Your shopping cart is empty

Subscriber login

Advanced Search

Return to the main site

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Generic Line > Pfizer Faces More Antitrust Suits For Blocking Generic on Effexor XR

Generic Line

June 20, 2012 | Vol. 29 No. 13

Pfizer Faces More Antitrust Suits For Blocking Generic on Effexor XR

Pfizer is again facing antitrust lawsuits from pharmacies claiming it used fraudulent tactics to block and delay generic forms of its blockbuster antidepressant Effexor XR.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

AstraZeneca Settles Seroquel XR Case Against Lupin AstraZeneca Loses U.S. Patent Protection for Asthma Drug Court Protects Pfizer’s Lyrica Through 2018 By Upholding Key Patents Retail Pharmacies Allege Pfizer, Ranbaxy Forestalled Generic Lipitor

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.